» Articles » PMID: 27838666

Morbidity and Mortality Due to Bordetella Pertussis: A Significant Pathogen in West Africa?

Overview
Journal Clin Infect Dis
Date 2016 Nov 14
PMID 27838666
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

In the absence of specific surveillance platforms for pertussis and availability of suitable diagnostics at the hospital level, reliable data that describe morbidity and mortality from pertussis are difficult to obtain in any setting, as is the case in West Africa. Here, we summarize the available evidence of the burden of pertussis in the region, given historical data, and describe recent and ongoing epidemiological studies that offer opportunities for additional data collection. The available seroepidemiological data provide evidence of ongoing circulation of Bordetella pertussis in the region. Due to the lack of systematic and targeted surveillance with laboratory confirmation of B. pertussis infection, we cannot definitively conclude that pertussis disease is well controlled in West Africa. However, based on observations by clinicians and ongoing demographic surveillance systems that capture morbidity and mortality data in general terms, currently there is no evidence that pertussis causes a significant burden of disease in young children in West Africa.

Citing Articles

Vaccine-Induced Cellular Immunity against Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Saso A, Kampmann B, Roetynck S Vaccines (Basel). 2021; 9(8).

PMID: 34452002 PMC: 8402596. DOI: 10.3390/vaccines9080877.

References
1.
Hallander H, Ljungman M, Storsaeter J, Gustafsson L . Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS. 2009; 117(11):797-807. DOI: 10.1111/j.1600-0463.2009.02530.x. View

2.
Mackenzie G, Plumb I, Sambou S, Saha D, Uchendu U, Akinsola B . Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. PLoS Med. 2012; 9(1):e1001161. PMC: 3260317. DOI: 10.1371/journal.pmed.1001161. View

3.
. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010; 85(40):385-400. View

4.
van Gageldonk P, van Schaijk F, van der Klis F, Berbers G . Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008; 335(1-2):79-89. DOI: 10.1016/j.jim.2008.02.018. View

5.
Muloiwa R, Dube F, Nicol M, Zar H, Hussey G . Incidence and Diagnosis of Pertussis in South African Children Hospitalized With Lower Respiratory Tract Infection. Pediatr Infect Dis J. 2016; 35(6):611-6. DOI: 10.1097/INF.0000000000001132. View